Clinical trials for IgA Nephropathy
58 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPhase 3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPhase 3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGPhase 2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPhase 4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPhase 2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc. · PI: Aditya Patel, MD
- RECRUITINGPhase 1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEarly Phase 1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital
- RECRUITINGPhase 3NCT06963827A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney ConditionTakeda · PI: Study Director
- RECRUITINGPhase 2NCT06983028Atacicept in Multiple Glomerular DiseasesVera Therapeutics, Inc. · PI: Pam Winterberg
- RECRUITINGN/ANCT07295808Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN)University Hospital, Limoges
- RECRUITINGNCT06926244RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)Assistance Publique - Hôpitaux de Paris
- RECRUITINGPhase 3NCT07024563Study of Ravulizumab in Pediatric Participants With Primary IgANAlexion Pharmaceuticals, Inc.
- RECRUITINGPhase 2NCT06676579Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)Mayo Clinic · PI: Fernando Fervenza, MD
- RECRUITINGPhase 3NCT07014826A Trial of HRS-5965 Capsule in Primary IgA NephropathyChengdu Suncadia Medicine Co., Ltd.
- RECRUITINGPhase 2NCT07020923Monthly Dosing of Atacicept in IgANVera Therapeutics, Inc. · PI: Zeeshan Khawaja
- RECRUITINGN/ANCT07056595Finerenone in Patients With IgA-nephropathy: Prospective Interventional TrialBotkin Hospital
- RECRUITINGPhase 3NCT06935357A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)Biogen · PI: Medical Director
- RECRUITINGNCT06952426A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the USNovartis Pharmaceuticals
- RECRUITINGPhase 2NCT06797518Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgANNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGPhase 4NCT06676384Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?Christian Medical College, Vellore, India · PI: Jonathan Barratt, PhD, FRCP
- RECRUITINGPhase 3NCT06819826A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with ProteinuriaBiocity Biopharmaceutics Co., Ltd.
- RECRUITINGPhase 4NCT06712407Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA NephropathyCalliditas Therapeutics AB · PI: Krassimir Mitchev
- RECRUITINGN/ANCT06654596Efficacy and Safety of Telitacicept in IgANRuijin Hospital
- ENROLLING BY INVITATIONPhase 2NCT06674577A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptVera Therapeutics, Inc. · PI: Zeeshan Khawaja
- RECRUITINGPhase 2NCT06740526Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney TissueOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGNCT06676007A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA NephropathySichuan Provincial People's Hospital
- RECRUITINGPhase 2NCT06670352Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- ACTIVE NOT RECRUITINGPhase 3NCT06564142Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)Alpine Immune Sciences Inc, A Subsidiary of Vertex
- ACTIVE NOT RECRUITINGPhase 3NCT07098897To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA NephropathyThe Affiliated Hospital of Xuzhou Medical University
- ACTIVE NOT RECRUITINGPhase 1NCT06209177Study of ARO-CFB in Adult Healthy VolunteersArrowhead Pharmaceuticals
- RECRUITINGPhase 3NCT06291376Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)Alexion Pharmaceuticals, Inc.
- RECRUITINGPhase 3NCT05510323Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKDAir Force Military Medical University, China
- ACTIVE NOT RECRUITINGPhase 2NCT06137768A Trial of HRS-5965 Tablets in Primary IgA NephropathyChengdu Suncadia Medicine Co., Ltd.
- RECRUITINGN/ANCT06767592A Study of Probiotics in IgA NephropathyUniversity of Leicester
- RECRUITINGPhase 3NCT05797610A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionHoffmann-La Roche · PI: Clinical Trials
- ACTIVE NOT RECRUITINGPhase 3NCT05852938A Study of Zigakibart in Adults With IgA NephropathyNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 3NCT04716231Atacicept in Subjects With IgA NephropathyVera Therapeutics, Inc. · PI: Zeeshan Khawaja
- RECRUITINGN/ANCT05791162Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA NephropathyCentre Hospitalier Universitaire de Besancon · PI: Melchior Chabannes, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05687890A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney DiseaseBiocity Biopharmaceutics Co., Ltd. · PI: Jianghua Chen, Prof
- RECRUITINGPhase 1NCT05942625A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy SubjectsHansoh BioMedical R&D Company
- RECRUITINGPhase 2NCT05775042Clinical Study of CM338 in the Treatment of Immunoglobulin A NephropathyKeymed Biosciences Co.Ltd · PI: Jicheng Lv
- RECRUITINGPhase 4NCT04662723Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.Fondazione Schena · PI: Francesco P Schena
- ACTIVE NOT RECRUITINGPhase 3NCT05799287A Study of Telitacicept for IgA Nephropathy (TELIGAN)RemeGen Co., Ltd. · PI: Jicheng Lv, M.D.
- RECRUITINGNCT05434325TESTING -ON Post-Trial ObservatioNal Cohort StudyThe George Institute · PI: Hong Zhang, Prof
- RECRUITINGNCT05234463Study of the Link Between Complement Activation and IgA Nephropathy SeverityUniversity Hospital, Strasbourg, France
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT05248659Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A NephropathyOtsuka Pharmaceutical Development & Commercialization, Inc.
- ACTIVE NOT RECRUITINGPhase 3NCT05248646Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)Otsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGPhase 3NCT04557462A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 3NCT04573478Atrasentan in Patients With IgA NephropathyChinook Therapeutics, Inc. · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 2NCT04663204A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A NephropathyUniversity of Leicester · PI: Chee Kay Cheung, MBChB PhD
- RECRUITINGNCT04858724The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)Ruijin Hospital · PI: Jingyuan Xie
- RECRUITINGNCT05190848Correlation of Microbiome and Metabonomics With IgA NephropathyGuangdong Provincial People's Hospital · PI: Xueqing Yu
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03418779Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRDGuang'anmen Hospital of China Academy of Chinese Medical Sciences · PI: Jie Wang
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03945318Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)Novartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 3NCT03762850A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyTravere Therapeutics, Inc. · PI: Radko Komers, MD, PhD
- RECRUITINGN/ANCT07074951Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathySt. Petersburg State Pavlov Medical University · PI: Vladimir Dobronravov, Professor, MD, PhD, DMedSci
- RECRUITINGNCT03001947IgA Nephropathy Registration Initiative of High Quality (INSIGHT)Sun Yat-sen University